Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Share-based Compensation (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Share-based Compensation for 15 consecutive years, with $301000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 276.25% year-over-year to $301000.0, compared with a TTM value of $634000.0 through Sep 2025, up 5.14%, and an annual FY2024 reading of $435000.0, down 84.46% over the prior year.
  • Share-based Compensation was $301000.0 for Q3 2025 at Alaunos Therapeutics, up from $184000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.3 million in Q2 2021 and bottomed at $68000.0 in Q1 2025.
  • Average Share-based Compensation over 5 years is $952105.3, with a median of $808000.0 recorded in 2022.
  • The sharpest move saw Share-based Compensation plummeted 88.98% in 2024, then surged 276.25% in 2025.
  • Year by year, Share-based Compensation stood at $917000.0 in 2021, then fell by 4.36% to $877000.0 in 2022, then crashed by 71.49% to $250000.0 in 2023, then crashed by 67.6% to $81000.0 in 2024, then soared by 271.6% to $301000.0 in 2025.
  • Business Quant data shows Share-based Compensation for TCRT at $301000.0 in Q3 2025, $184000.0 in Q2 2025, and $68000.0 in Q1 2025.